Laboratory Tests for Discharge After Cerebral Dural Sinus Thrombosis
Order a complete blood count with platelets, coagulation panel (PT/INR, aPTT, fibrinogen, D-dimer), comprehensive metabolic panel, and thrombophilia screening if not already completed during acute hospitalization. 1
Essential Baseline Labs
For a 35-year-old man being discharged after treatment for cerebral dural sinus thrombosis, the following laboratory tests are critical:
Immediate/Discharge Labs
Complete blood count (CBC) with differential and platelets - Essential to monitor for thrombocytopenia and ensure platelet count is adequate (>150×10⁹/L is reassuring) 2
Coagulation panel:
- Prothrombin time (PT) and INR - Critical for monitoring anticoagulation therapy 1, 3
- Activated partial thromboplastin time (aPTT) - Baseline coagulation assessment 1
- Fibrinogen level - Should be checked as part of comprehensive coagulation assessment 2
- D-dimer - While elevated acutely, provides baseline for comparison 2, 1
Comprehensive metabolic panel - Including renal function (creatinine), liver function tests (AST, ALT, bilirubin), and electrolytes 4
Thrombophilia Workup (if not done acutely)
This is particularly important in a 35-year-old with unprovoked thrombosis:
- Protein C and S levels - Screen for inherited thrombophilia 3
- Antithrombin III level
- Factor V Leiden mutation
- Prothrombin G20210A mutation
- Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, anti-β2 glycoprotein I) - Critical for determining duration of anticoagulation 3
- Homocysteine level
Important caveat: Thrombophilia testing should ideally be performed after acute anticoagulation is completed or at least 2-4 weeks after the acute event, as acute thrombosis and anticoagulation can affect results. However, obtaining baseline samples before discharge is reasonable if follow-up compliance is uncertain.
Additional Considerations
If Not Already Performed
- Fasting lipid panel - Part of comprehensive vascular risk assessment 4
- Hemoglobin A1C - Screen for diabetes as cardiovascular risk factor 4
- Inflammatory markers (ESR, CRP) - Only if age >50 years or clinical suspicion of vasculitis/inflammatory condition 4
Monitoring Anticoagulation
The specific anticoagulation monitoring depends on the agent:
- If on warfarin: INR target 2-3, with close monitoring initially 3
- If on direct oral anticoagulants (DOACs): No routine monitoring required, but baseline renal and hepatic function essential 5
- If on low molecular weight heparin (LMWH): Consider anti-Xa levels only if renal impairment, obesity, or pregnancy 6
Duration of Anticoagulation Context
The thrombophilia results will directly inform anticoagulation duration 3:
- Transient risk factor (e.g., infection, dehydration): 3-6 months anticoagulation
- Idiopathic or mild thrombophilia: 6-12 months anticoagulation
- Severe thrombophilia (antiphospholipid syndrome, multiple abnormalities): Lifelong anticoagulation
Common Pitfalls to Avoid
Do not order thrombophilia testing during acute anticoagulation if you need accurate results - protein C, protein S, and antithrombin levels are artificially lowered by warfarin and acute thrombosis. However, genetic testing (Factor V Leiden, prothrombin mutation) can be done anytime.
Do not skip platelet count monitoring - Even though this patient likely doesn't have vaccine-induced immune thrombotic thrombocytopenia (VITT), approximately 5% of thrombosis patients can have delayed thrombocytopenia 2.
Do not forget to assess for underlying malignancy in unprovoked thrombosis - While not routine discharge labs, age-appropriate cancer screening should be current, and unexplained weight loss, anemia, or elevated inflammatory markers warrant further investigation.